Vis enkel innførsel

dc.contributor.authorHelgadottir, Holmfridur
dc.contributor.authorLund, Sigrun H
dc.contributor.authorGizurason, Sveinbjørn
dc.contributor.authorWaldum, Helge
dc.contributor.authorBjörnsson, Einar B
dc.date.accessioned2021-04-08T08:23:47Z
dc.date.available2021-04-08T08:23:47Z
dc.date.created2020-12-18T16:17:58Z
dc.date.issued2020
dc.identifier.citationScandinavian Journal of Gastroenterology. 2020, 1-9.en_US
dc.identifier.issn0036-5521
dc.identifier.urihttps://hdl.handle.net/11250/2736760
dc.description.abstractObjective Gastrin elevation secondary to proton pump inhibitor (PPI) therapy is well documented. Recent studies have demonstrated a sex-related difference where females on PPIs have significantly higher baseline gastrin levels than males. The aim of the study was to analyse the pharmacokinetics of esomeprazole and short-term effect on serum gastrin levels and evaluate potential sex-related difference. Materials and methods Healthy volunteers received 40 mg of esomeprazole daily for five days. After the 1st and 5th dose blood samples for fasting gastrin and pharmacokinetic analysis were collected at scheduled time-points for eight hours. Esomeprazole was analysed by liquid chromatography and gastrin concentrations were measured using radioimmunoassay. Results A total of 30 volunteers were enrolled. Females had higher median baseline gastrin (pM) than males 12 (IQR 10–15) vs. 7 (IQR 4–11) (p = .03). In the study cohort, median gastrin levels rose from 10 (IQR 6–14) to 15 (IQR 13–20) (p = .0002). The serum levels for esomeprazole increased by an average of 299.8 ng/mL (p < .001) from day 1 to day 5. Comparison of the esomeprazole pharmacokinetic parameters between males and females revealed no significant sex-related differences. No significant correlation was found between the AUC and the gastrin level on day 5 (p = .15). Conclusions In healthy volunteers, serum gastrin increased significantly after a four-day PPI-therapy. There was also a significant increase in serum esomeprazole from day 1 to day 5. The increase in gastrin and esomeprazole concentration was not related to sex and no significant sex-related difference was found in terms of pharmacokinetic parameters. European Clinical Trial Database (2015-002230-41).en_US
dc.language.isoengen_US
dc.publisherTaylor & Francisen_US
dc.titlePharmacokinetics of single and repeated oral doses of esomeprazole and gastrin elevation in healthy males and femalesen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.source.pagenumber1-9en_US
dc.source.journalScandinavian Journal of Gastroenterologyen_US
dc.identifier.doi10.1080/00365521.2020.1859610
dc.identifier.cristin1861729
dc.description.localcodeThis article will not be available due to copyright restrictions (c) 2020 by T&Fen_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel